Pharma BD Deal Intelligence

AbbVie Inc. / Stemcentrx Inc.

2012 · Acquisition/Merger · $5.8B · Complete

AbbVie's $5.8B bet on Stemcentrx delivered rovalpituzumab tesirine, an anti-DLL3 antibody-drug conjugate for small cell lung cancer that ultimately failed in Phase 3 and was discontinued—one of oncology's costliest clinical washouts, reflected in depressed critic and outcome scores.

CALLED IT — OFF BY 9
Full analysis, sources & comparables →
Top 10 biggest flops we track

Ranks computed across 828 graded deals (Critic + Outcome Score both present).

The coverage arc

Nov 17, 2012 Wikipedia Neutral

AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.

Apr 29, 2016 The Cancer Letter Neutral

AbbVie acquired Stemcentrx for its novel late-stage Rova-T compound showing 44% response rates in DLL3-expressing small cell lung cancer — an area of enormous…

Sep 04, 2019 pharmaphorum Bearish

Rova-T: the story of AbbVie's multi-billion dollar failure. Even without hindsight, buying Stemcentrx outright for $5.8B based on Phase 1 data looked bold at…

Source summaries from our enrichment pipeline; follow links for originals.

All 5 sources with sentiment breakdown →

AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.

Key facts

Disease & market context

Solid Tumors (DLL3+)

Competitive Landscape

DLL3+ solid tumors: Rova-T (rovalpituzumab tesirine, AbbVie/Stemcentrx lead asset) discontinued after Phase 3 failures in SCLC (TAHOE, MERU trials 2018-2019). The DLL3 target was ultimately validated in a different format: Amgen's tarlatamab (Imdelltra, DLL3×CD3 BiTE, FDA-approved May 2024 for small cell lung cancer 2L+). Other DLL3-directed programs in development include Boehringer Ingelheim (BI 764532), Harpoon's HPN328 (licensed to Merck as MK-6070), and Phanes Therapeutics. Stemcentrx's other DLL3 assets (SC-002, SC-003) discontinued. AbbVie's $5.8B Stemcentrx bet was written down substantially after Rova-T failures.

Oncology Stem Cell Platform

Competitive Landscape

AbbVie/Stemcentrx was a platform acquisition focused on Rova-T (DLL3 ADC; discontinued post-Phase-3 failure) and the broader tumor-initiating-cell platform. Competitive landscape applies per sub-asset: see the Solid Tumors (DLL3+) row for DLL3 competitor framing (Amgen tarlatamab/Imdelltra, Imdelltra competitors).

Small Cell Lung Cancer

Competitive Landscape

Small cell lung cancer (SCLC) is a historically stagnant ~$3B market recently reshaped by immunotherapy and DLL3-targeted agents. Platinum-etoposide chemotherapy remains the chemo backbone in both extensive-stage (ES-SCLC) and limited-stage (LS-SCLC) disease. Anti-PD-L1 + chemo (1L ES-SCLC standard): atezolizumab (Tecentriq, Roche; IMpower133, approved March 2019) and durvalumab (Imfinzi, AstraZeneca; CASPIAN, approved March 2020). Anti-PD-1 consolidation: durvalumab (Imfinzi, AstraZeneca; ADRIATIC LS-SCLC consolidation, FDA-approved December 2024) and pembrolizumab (Keytruda, Merck; post-platinum 3L). DLL3-targeted therapies (direct class to Rova-T): tarlatamab (Imdelltra, Amgen; DLL3xCD3 bispecific T-cell engager) received FDA accelerated approval May 2024 for 2L+ ES-SCLC based on DeLLphi-301, representing the successful MOA Rova-T failed to achieve. Chemotherapy (2L+): lurbinectedin (Zepzelca, Jazz Pharmaceuticals; approved 2020, ~$300M 2023) and topotecan (generic). PARP inhibitors: olaparib (Lynparza, AZ/Merck) studied but not approved in SCLC. Rova-T was discontinued 2019 after TAHOE and MERU Phase 3 failures, vacating the DLL3 ADC space; Amgen's tarlatamab ultimately validated DLL3 as a target with a superior MOA format (bispecific vs. ADC).

Deal timeline

Related deals — scored

DealYearValueOutcome
AbbVie Inc. / Stemcentrx Inc. (this deal)2012$5.8B16
AbbVie Inc. / Boehringer Ingelheim GmbH2016$2.2B95
AbbVie Inc. / Genmab A/S2020$3.9B81
AbbVie Inc. / Pharmacyclics Inc.2015$21.0B79
AbbVie Inc. / Apogee Therapeutics, Inc.2026$10.9B72
AbbVie Inc. / ImmunoGen Inc.2023$10.1B69
AbbVie Inc. / Gilgamesh Pharmaceuticals Inc.2024$2.0B64

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →